Bayer (BAYRY) announced encouraging detailed results from the late-stage FINEARTS-HF study on finerenone.Finerenone is marketed as Kerendia or Firialta in some countries. The drug is approved for the treatment of adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in more than 90 countries worldwide, including China, Europe, Japan and the United States.It is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist that has been shown to block the harmful effec ...